LLLina Helena Lankhorst

Lina Helena Lankhorst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lina Helena Lankhorst has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Healthcare professionals’ views on the use of whole genome sequencing for adolescents and young adults with advanced cancer

    by Lina H. Lankhorst, Isabella F.V. Olgers, Noor A.A. Giesbertz, Winette T.A. van der Graaf, Olga Husson

  • Open Access

    Introducing Whole Genome Sequencing to Adolescents and Young Adults (AYA) with Poor-prognosis Cancer into Standard Oncology Care: What do they know, expect and value?

    by Lina Helena Lankhorst, Helle-Brit Fiebrich-Westra, Irene E.G. van Hellemond, Noor A.A. Giesbertz, Lizet E. van der Kolk, Leyla Azarang, Winette van der Graaf, Olga Husson

    Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.

  • Open Access

    Perspectives of adolescents and young adults with advanced cancer on complete genomic analysis in standard oncology care

    by Lina H Lankhorst, Milou J P Reuvers, Noor A A Giesbertz, Lizet E van der Kolk, Helle-Brit Fiebrich-Westra, Mathijs P Hendriks, Baukje Flameling, Lenneke Stabel, Madelief van de Ree, Jelmer Gietema, et al.

    Purpose Tumour genomic profiling, including whole genome sequencing (WGS), offers opportunities for refined diagnosis and personalised treatment for adolescents and young adults (AYAs) with advanced or poor prognostic cancer. This study explores AYAs’ attitudes towards receiving WGS in standard oncological care, their preferences for the communication of results and the perceived impact of these results. Methods Semistructured interviews were conducted with AYAs (aged 18–39 years at initial cancer diagnosis). Interviews were transcribed and analysed thematically using an inductive approach in NVivo (V.12). Results 16 AYAs participated. Analysis revealed five themes: (1) confidence in the current WGS procedure; (2) challenges in understanding and communicating purpose and results of WGS; (3) dual emotional impact of WGS results; (4) high value placed on hereditary information for self and loved ones and (5) balancing altruism and personal risk in genomic data sharing. Conclusion AYAs with advanced cancer generally value WGS, even when results have no immediate clinical consequences. They describe benefits such as hope, reassurance and the opportunity to help future patients. However, misunderstandings about its purpose, difficulties in interpreting genomic findings and limited awareness of potential hereditary implications may limit its optimal use. Strengthening communication with age-appropriate, accessible explanatory materials will be essential to ensure AYAs understand the purpose and potential outcomes of WGS and can fully benefit from its implementation.


  • Open Access

    Genomic distinctions in adolescent and young adult cancer: A comprehensive review

    by Jeffrey van Putten, Lina H. Lankhorst, Adrianus Johannes de Langen, Anthonie J. van der Wekken, Jeanine Roodhart, Karen Bolhuis, Sjoukje F. Oosting, Marloes van Dongen, Marleen Kok, Marjolein Geurts, et al.


  • Open Access

    Core Patient-Centered Outcomes for Adolescents and Young Adults with Cancer: A Comprehensive Review of the Literature from the STRONG-AYA Project

    by Silvie H. M. Janssen, Winette T. A. van der Graaf, Anna Hurley-Wallace, Carla Vlooswijk, Catarina S. Padilla, Charlotte Cairns, Connor J. Tyler, Emily I. Holthuis, Gudrun E. Rohde, Katherine J. Hunt, et al.

    Background: In adolescents and young adults (AYAs) with cancer, the importance of patient-centered research outcomes is increasingly acknowledged and there is a need for consensus on the most relevant outcomes. This review provides a comprehensive overview of outcomes relevant to AYAs with cancer in order to develop an AYA-specific core outcome set (COS) as part of the European project STRONG-AYA. Methods: A literature search was conducted to identify relevant articles in five databases. Each article was reviewed by two independent researchers, using Rayyan (an online tool) to screen articles by their title/abstract and then by their full text. Subsequently, the data were extracted using a predefined, tailored extraction framework. Results: In total, 17,301 articles were screened, of which 1631 were included in the analyses. Registry studies (52.9%) were the most used study type. Well-represented continents were North America (50.3%) and Europe (27.8%). Of the five core areas, functioning (47.0%) and epidemiology (44.9%) were covered most often, followed by physiological/clinical (42.4%), resource use (6.1%), and adverse events (4.5%). The outcome domains that were represented the most include mortality/survival (43.1%), delivery of care (23.4%), outcomes relating to neoplasms (22.7%), and emotional functioning/well-being (19.2%). Conclusions: This literature review provides a foundation for the development of an AYA-specific COS for improving the relevance and efficiency of measuring outcomes, the pooling of (international) research data, and the value of care for current and future AYAs with cancer. Finalization and refinement of the COS should be a priority for future research.


  • Open Access

    Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma

    by Lindy Vernooij, Alvin Kamili, Kimberley Ober, Jennemiek van Arkel, Lina Lankhorst, Enya Vermeulen, Hanin Al-Khakany, Gabor Tax, Marlinde L. van Den Boogaard, Jamie I. Fletcher, et al.


  • Top Cited Papers

    Exploiting senescence for the treatment of cancer

    by Liqin Wang, Lina Lankhorst, René Bernards

    Senescence is a cellular response to a variety of stress signals that is characterized by a stable withdrawal from the cell cycle and major changes in cell morphology and physiology. While most research on senescence has been performed on non-cancer cells, it is evident that cancer cells can also mount a senescence response. In this Review, we discuss how senescence can be induced in cancer cells. We describe the distinctive features of senescent cancer cells and how these changes in cellular physiology might be exploited for the selective eradication of these cells (senolysis). We discuss activation of the host immune system as a particularly attractive way to clear senescent cancer cells. Finally, we consider the challenges and opportunities provided by a ‘one-two punch’ sequential treatment of cancer with pro-senescence therapy followed by senolytic therapy.